Notably, the DKC1 inhibitor pyrazofurin and the MEK1/2 inhibitor trametinib can synergistically suppress colorectal cancer growth, suggesting the Ψ synthases are very promising therapeutic targets for cancer (Kan et al., 2021). This evidence concerns the gene MAP2K1 and cancer.